Cantor Fitzgerald initiated coverage of Humana with an Overweight rating and $597 price target. The stock is undervalued given the "multiple levers of upside" to management’s guidance of 14% annual earnings growth through 2025, the analyst tells investors in a research note. The firm sees the potential Medicare Advantage share gains and CenterWell revenue synergies.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on HUM:
- Humana price target raised to $590 from $560 at Truist
- Humana price target raised to $637 from $620 at Morgan Stanley
- Morgan Stanley says Humana could trade up by mid-single digits on final MA rates
- Final Medicare Advantage rates positive for managed care, says JPMorgan
- Ohio AG Yost sues Express Scripts, Prime Therapeutics over drug price fixing